/
Oncology
Mantle Cell Lymphoma
49
Pipeline Programs↗
90
Active Trials↗
40
Companies Involved↗
Mantle Cell Lymphoma is a moderately active landscape with 49 programs across 40 companies. The most active players are Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 13
Phase 224
Phase 315
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
37 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 96% of 49 pipeline programs.
Analysis
Trial Status
262
clinical trials
Completed113 · 43%
Recruiting46 · 18%
Active, not recruiting30 · 11%
Terminated26 · 10%
Unknown status22 · 8%
Not yet recruiting13 · 5%
Other12 · 5%
Clinical Trials
Trial Activity
262 trials
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study of Orelabrutinib in Combination With Obinutuzumab and Short-course Venetoclax in Patients With Treatment-naïve Mantle Cell Lymphoma (MCL)
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07719556·39 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)